When 21‑year‑old Mason Henderson of Evadale, Texas, was diagnosed with a rare diffuse hemispheric glioma, his doctors turned to a precision‑medicine approach. After surgery, radiation and chemotherapy failed to halt the tumor’s spread, the neuro‑oncology team at Baylor College of Medicine and NYU Langone Health prescribed Lynparza (olaparib) – a drug originally approved for ovarian cancer but shown in early studies to target the genetic flaw in Henderson’s tumor.
Insurance refusal stalls promising therapy
Despite a detailed justification from Dr. Jacob Mandel and Dr. Jessica Schulte, the pharmacy benefit manager Liviniti denied coverage on Jan. 30, stating the medication “is not approved for the diagnosis provided.” The out‑of‑pocket cost would be roughly $8,700 per month, a burden the family could not bear.
Henderson’s stepfather, Jerry Lowe, who serves as a helicopter pilot for the Jefferson County sheriff’s office, appealed the decision to the county’s health‑plan review board. The board appointed an independent medical reviewer, who nonetheless supported the denial and suggested an alternative drug that the treating physicians felt would not be effective. The board has not responded to further requests for comment.
Local impact of a national issue
Henderson’s case underscores a broader problem for Texas patients with rare cancers. Insurers typically rely on FDA labels and established clinical guidelines to determine reimbursement. When a tumor is so uncommon that no standard of care exists, insurers often lack a clear pathway, leaving families to navigate costly appeals.
“Insurance coverage routinely trails behind what genomic testing reveals about a patient’s cancer and what the science supports,” said Olivier Elemento, director of the Englander Institute for Precision Medicine at Weill Cornell Medicine. He noted that while the FDA has begun approving “tissue‑agnostic” drugs for specific genetic mutations, such approvals remain a small fraction of all cancer therapies.
Hope from research and basket trials
Nationally, researchers are expanding “basket trials,” which match patients to drugs based on tumor genetics rather than organ of origin. The American Society of Clinical Oncology’s TAPUR program has enrolled over 3,000 patients, providing off‑label treatments at no cost to participants. About half of those patients have seen benefit, and successful outcomes have prompted updates to treatment guidelines – a step that can eventually open the door to insurance reimbursement.
For families like the Lowes, however, the lag between scientific breakthroughs and payer policies can be life‑changing. “Mason was a healthy, athletic young man with a strong faith in Jesus and a love for his community,” his mother Tabitha Lowe said. “He wanted to serve as a police officer. We are fighting for him to get the care he deserves.”
What’s next?
The Henderson family continues to seek coverage for Lynparza while exploring clinical trial options. Their story highlights the need for Texas insurers to adapt quickly to precision‑medicine advances, ensuring that patients with rare, genetically defined cancers are not left without viable treatment options.
Original reporting: Texarkana Gazette — read the source article.
